ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 2, 2008, Pages 398-404

  Kato, Masaki ^a,b   Fukuda, Tsuyoshi ^c   Serretti, Alessandro ^b   Wakeno, Masataka ^a   Okugawa, Gaku ^a   Ikenaga, Yuka ^c   Hosoi, Yuka ^c   Takekita, Yoshiteru ^a   Mandelli, Laura ^b   Azuma, Junichi ^c   Kinoshita, Toshihiko ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

ABCB1; Blood brain barrier; Depression; Haplotype; Paroxetine; Treatment response

Indexed keywords

GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; PAROXETINE;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG DOSE INCREASE; FEMALE; GENETIC VARIABILITY; HAMILTON SCALE; HAPLOTYPE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE, MULTIPLE; FEMALE; GENES, MDR; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PAROXETINE; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS; TREATMENT OUTCOME; VARIATION (GENETICS);

EID: 38749113409     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.09.003     Document Type: Article

References (50)

1. Adli M., Baethge C., Heinz A., Langlitz N., and Bauer M. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci 255 6 (2005) 387-400
2. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association. Am J Psychiatry 157 4 Suppl (2000) 1-45
3. Asano T., Takahashi K.A., Fujioka M., Inoue S., Okamoto M., Sugioka N., et al. ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics 13 11 (2003) 675-682
4. Barrett J.C., Fry B., Maller J., and Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21 2 (2005) 263-265
5. Bolo N.R., Hode Y., Nedelec J.F., Laine E., Wagner G., and Macher J.P. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 23 4 (2000) 428-438
6. Cascorbi I., Gerloff T., Johne A., Meisel C., Hoffmeyer S., Schwab M., et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69 3 (2001) 169-174
7. Catafau A.M., Perez V., Plaza P., Pascual J.C., Bullich S., Suarez M., et al. Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study. Psychopharmacology (Berl) 189 2 (2006) 145-153
8. Cavalli Sforza L. The history and geography of human genes (1994), Princeton University Press, Princeton, New Jersey, USA
9. Cohen J. Statistical power analysis for the behavioral sciences (1988), Lawrence Erlbaum Associates, Hillsdale, New Jersey
10. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86 2 (1989) 695-698
11. Deckert J., Catalano M., Heils A., Di Bella D., Friess F., Politi E., et al. Functional promoter polymorphism of the human serotonin transporter: lack of association with panic disorder. Psychiatr Genet 7 1 (1997) 45-47
12. De Luca V., Mundo E., Trakalo J., Wong G.W., and Kennedy J.L. Investigation of polymorphism in the MDR1 gene and antidepressant-induced mania. Pharmacogenomics J 3 5 (2003) 297-299
13. Drescher S., Schaeffeler E., Hitzl M., Hofmann U., Schwab M., Brinkmann U., et al. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 53 5 (2002) 526-534
14. Farrell R.J., Murphy A., Long A., Donnelly S., Cherikuri A., O'Toole D., et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 118 2 (2000) 279-288
15. First M.B., Spitzer R.L., Gibbon M., and Williams J.B. Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P, Version 2.0) (1995), Biometrics Research Department, New York State Psychiatric Institute, New York
16. Franchini L., Serretti A., Gasperini M., and Smeraldi E. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res 32 5 (1998) 255-259
17. Goto M., Masuda S., Saito H., Uemoto S., Kiuchi T., Tanaka K., et al. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 12 6 (2002) 451-457
18. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6 (1967) 278-296
19. Hitzl M., Drescher S., van der Kuip H., Schaffeler E., Fischer J., Schwab M., et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 11 4 (2001) 293-298
20. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmoller J., Johne A., et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97 7 (2000) 3473-3478
21. Horinouchi M., Sakaeda T., Nakamura T., Morita Y., Tamura T., Aoyama N., et al. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res 19 10 (2002) 1581-1585
22. Kaplan B., Lown K., Craig R., Abecassis M., Kaufman D., Leventhal J., et al. Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. Transplantation 67 2 (1999) 333-335
23. Kato M., Fukuda T., Wakeno M., Fukuda K., Okugawa G., Ikenaga Y., et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. Neuropsychobiology 53 4 (2006) 186-195
24. Kimchi-Sarfaty C., Oh J.M., Kim I.W., Sauna Z.E., Calcagno A.M., Ambudkar S.V., et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315 5811 (2007) 525-528
25. Laika B., Leucht S., and Steimer W. ABCB1 (P-glycoprotein/MDR1) gene G2677T/a sequence variation (polymorphism): lack of association with side effects and therapeutic response in depressed inpatients treated with amitriptyline. Clin Chem 52 5 (2006) 893-895
26. Lin P.I., Vance J.M., Pericak-Vance M.A., and Martin E.R. No gene is an island: the flip-flop phenomenon. Am J Hum Genet 80 3 (2007) 531-538
27. Maines L.W., Antonetti D.A., Wolpert E.B., and Smith C.D. Evaluation of the role of P-glycoprotein in the uptake of paroxetine, clozapine, phenytoin and carbamazapine by bovine retinal endothelial cells. Neuropharmacology 49 5 (2005) 610-617
28. Marzolini C., Paus E., Buclin T., and Kim R.B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75 1 (2004) 13-33
29. Moriya Y., Nakamura T., Horinouchi M., Sakaeda T., Tamura T., Aoyama N., et al. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol Pharm Bull 25 10 (2002) 1356-1359
30. Normann C., Horn M., Hummel B., Grunze H., and Walden J. Paroxetine in major depression: correlating plasma concentrations and clinical response. Pharmacopsychiatry 37 3 (2004) 134-138
31. O'Reilly R.L., Bogue L., and Singh S.M. Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biol Psychiatry 36 7 (1994) 467-471
32. Pare C.M., Rees L., and Sainsbury M.J. Differentiation of two genetically specific types of depression by the response to anti-depressants. Lancet 2 (1962) 1340-1343
33. Rao V.V., Dahlheimer J.L., Bardgett M.E., Snyder A.Z., Finch R.A., Sartorelli A.C., et al. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinal-fluid drug-permeability barrier. Proc Natl Acad Sci U S A 96 7 (1999) 3900-3905
34. Sakaeda T., Nakamura T., Horinouchi M., Kakumoto M., Ohmoto N., Sakai T., et al. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 18 10 (2001) 1400-1404
35. Salama N.N., Yang Z., Bui T., and Ho R.J. MDR1 haplotypes significantly minimize intracellular uptake and transcellular P-gp substrate transport in recombinant LLC-PK1 cells. J Pharm Sci 95 10 (2006) 2293-2308
36. Sartorius N. The economic and social burden of depression. J Clin Psychiatry 62 Suppl 15 (2001) 8-11
37. Schwab M., Eichelbaum M., and Fromm M.F. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol 43 (2003) 285-307
38. Serretti A., Franchini L., Gasperini M., Rampoldi R., and Smeraldi E. Mode of inheritance in mood disorders families according to fluvoxamine response. Acta Psychiatr Scand 98 6 (1998) 443-450
39. Serretti A., Artioli P., and Quartesan R. Pharmacogenetics in the treatment of depression: pharmacodynamic studies. Pharmacogenet Genomics 15 2 (2005) 61-67
40. Serretti A., Kato M., De Ronchi D., and Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 12 3 (2007) 247-257
41. Siegmund W., Ludwig K., Giessmann T., Dazert P., Schroeder E., Sperker B., et al. The effects of the human MDR1 genotype on the expression of duodenal P-glycoprotein and disposition of the probe drug talinolol. Clin Pharmacol Ther 72 5 (2002) 572-583
42. Strauss W.L., Layton M.E., and Dager S.R. Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy. Am J Psychiatry 155 3 (1998) 380-384
43. Tanabe M., Ieiri I., Nagata N., Inoue K., Ito S., Kanamori Y., et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297 3 (2001) 1137-1143
44. Tang K., Ngoi S.M., Gwee P.C., Chua J.M., Lee E.J., Chong S.S., et al. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics 12 6 (2002) 437-450
45. Uhr M., Grauer M.T., and Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 54 8 (2003) 840-846
46. Ustun T.B. The worldwide burden of depression in the 21st century. In: Weismann M.M. (Ed). Treatment of depression: bridging the 21st Century (2001), American Psychiatric Press, Washington, DC 35-45
47. Weiss J., Dormann S.M., Martin-Facklam M., Kerpen C.J., Ketabi-Kiyanvash N., and Haefeli W.E. Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305 1 (2003) 197-204
48. Westphal K., Weinbrenner A., Giessmann T., Stuhr M., Franke G., Zschiesche M., et al. Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 68 1 (2000) 6-12
49. Yasui-Furukori N., Saito M., Nakagami T., Kaneda A., Tateishi T., and Kaneko S. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 30 2 (2006) 286-291
50. Yasui-Furukori N., Tsuchimine S., Saito M., Nakagami T., Sato Y., and Kaneko S. Association between major Multidrug Resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 31 6 (2007) 1230-1234